相关实验视频

Updated: Jan 6, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

通过调节IRF9/IFI6轴,TAMs衍生的外体促进乳腺癌的进展

Xingjuan Zhao¹, Yajue Wang¹, Xuan Yang¹

¹Department of Mammary Gland, Shanxi Provincial People's Hospital, Taiyuan City, 030012, Shanxi Province, China.

Breast cancer (Tokyo, Japan)

|October 2, 2025

概括

与瘤相关的巨细胞 (TAMs) 释放含有干扰素α诱导蛋白6 (IFI6) 的外体,该蛋白驱动乳腺癌 (BC) 的进展. 这通过干扰素调节因子9 (IRF9) /IFI6轴发生,突出了BC的新治疗标.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
分子生物学分子生物学

背景情况:

乳腺癌 (BC) 是全球女性癌症相关死亡的主要原因.
瘤微环境,特别是与瘤相关的巨细胞 (TAMs) 和它们的外体,在BC进展中起着至关重要的作用.
通过TAM衍生的外基因组影响BC的确切机制仍然不完全理解.

研究的目的:

阐明TAM衍生的外体在调节乳腺癌 (BC) 进展中的作用.
在BC进步中调查涉及TAM衍生的外体的特定分子机制.
在这个过程中确定关键的分子参与者,如干扰素调节因子9 (IRF9) 和干扰素α诱导蛋白6 (IFI6).

主要方法:

外体从TAM中分离出来并进行了表征.
在体外测试 (EdU,Transwell,流细胞计) 评估了BC细胞的增殖,迁移,入侵,亡和活性氧物种 (ROS) 水平.
用RT-qPCR,西部抹杀,双露西法酶记者测定和染色体免疫沉 (ChIP) 来分析基因和蛋白质表达和相互作用.
用小鼠异种移植模型在体内验证BC瘤生长中的IRF9/IFI6轴.

主要成果:

发现TAMs衍生的外基因组富含干扰素α诱导蛋白6 (IFI6).
从TAMs传播的外体IFI6促进了BC细胞的增殖,迁移和糖解,同时抑制了细胞亡和ROS积累.
干扰素调节因子9 (IRF9) 被确定为TAM中IFI6转录的促进者,TAM衍生的外体内IRF9/IFI6轴被证明在体外和体内都能推动BC进展.

结论:

由TAM衍生的外体通过IRF9/IFI6信号轴促进乳腺癌的进展.
在TAM衍生的外体中准IRF9/IFI6轴为乳腺癌的潜在治疗策略.
了解TAM和BC细胞通过外体细胞之间的复杂通信对于开发新型癌症治疗非常重要.

关键词:

乳腺癌乳腺癌乳腺癌异构体是什么? 异构体是什么? 外构体是什么?第六章十五章十五章在 IRF9 中,IRF9 是 IRF9 的第一个类型.这就是TAMs.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...